Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,584,707
-
Total 13F shares
-
93,921
-
Share change
-
+93,841
-
Total reported value
-
$249,543
-
Price per share
-
$2.67
-
Number of holders
-
13
-
Value change
-
+$249,328
-
Number of buys
-
12
Institutional Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) as of Q4 2023
As of 31 Dec 2023,
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,921 shares.
The largest 10 holders included
Altium Capital Management LP, ACADIAN ASSET MANAGEMENT LLC, Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC, McIlrath & Eck, LLC, Tower Research Capital LLC (TRC), OSAIC HOLDINGS, INC., MORGAN STANLEY, WELLS FARGO & COMPANY/MN, and BlackRock Inc..
This page lists
13
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.